XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Operations (Unaudited)
$ in Thousands
3 Months Ended
Mar. 31, 2022
USD ($)
shares
Mar. 31, 2022
$ / shares
Mar. 31, 2021
USD ($)
shares
Mar. 31, 2021
$ / shares
Revenue:        
Net product sales $ 78,715   $ 66,402  
Cost of goods sold 7,582   6,539  
Gross profit 71,133   59,863  
Operating expenses:        
Research and development 81,517   64,117  
Selling, general, and administrative 58,116   46,726  
Changes in fair value of contingent consideration payable (1,188)   471  
Loss on impairment of assets 6,616   0  
Depreciation and amortization 1,411   1,604  
Total operating expenses 146,472   112,918  
Loss from operations (75,339)   (53,055)  
Other (expense) income:        
Interest income 133   165  
Interest expense (8,147)   (7,992)  
Other income (expense) 1,902   (3,200)  
Loss before income tax (81,451)   (64,082)  
Income tax expense (3,809)   (1,582)  
Net loss attributable to common stockholders $ (85,260)   $ (65,664)  
Net loss attributable to common stockholders per common share - basic (in dollars per share) | $ / shares   $ (0.30)   $ (0.25)
Net loss attributable to common stockholders per common share — diluted (in dollars per share) | $ / shares   $ (0.30)   $ (0.25)
Weighted average common shares outstanding - basic (in shares) | shares 288,481,741   264,369,317  
Weighted average number of shares outstanding - diluted (in shares) | shares 288,481,741   264,369,317